Fabiana Piscitelli Via Udine 16, 81034 Mondragone (CE) Telephone 081-8675193 (lab.) Fax 081-8041770 E-mail [email protected] pec [email protected] Citizenship Italiana Birth date and place 18/02/1985 Naples

Professional experience 17/03/14 - present

Researcher Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche “Bioavailability of Aliamides, natual and synthetic, from blood by spectroscopic and chromatographic tecniques”

03/01/13 - 21/04/14 Fellowship Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche “Bioavailability of Aliamides, natual and synthetic, from blood by spectroscopic and chromatographic tecniques” 03/01/11 - 02/01/13 Fellowship Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche “Chemical and pharmacological characterization of Cannabis extracts” 11/04/12 - 29/06/12 Stage The Scripps Research Institute, San Diego (CA) USA Metabolic profiling by ABPP assay (Activity-based protein profiling) and MudPIT (multidimensional protein identification technology) 02/03/09 - 31/12/10 Fellowship Glures, srl “Realization of a pilot plant for testing sustainable processes of biorefinery” 01/06/07 - 30/09/07 Fellowship Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche “Identification of analytical procedures for purification and quantification, by LC-MSMS, of triglycerides from Cannabis sativa extracts” 05/03/07 - 04/05/07 Contratto di collaborazione coordinata e continuativa Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche

“Identification of analytical procedures for purification and quantification, by LC-MSMS, of triglycerides from Cannabis sativa extracts”

Education 2009-2013

PhD in Neurobiology Università degli Studi dell’Insubria Thesis: “Endocannabinoidomics: a targeted lipidomics method for the study of endocannabinoid-related molecules in the CNS. “ Supervisors: Prof.ssa Daniela Parolaro, Dott.ssa Alessia Ligresti

2006-2008

Master degree in Chemical Sciences (LS) (110/110 e lode) Università degli Studi di Napoli Federico II Thesis: “Alterations of endocannabinoid and related lipid levels in metabolic disorders: studies in animal models and obese patients.” Supervisors: Prof. Piero Pucci, Dott. Vincenzo Di Marzo

2003-2006

Master degree in Chemistry (106/110) Università degli Studi di Napoli Federico II Thesisi: “Proteomics methodologies based on LC/MS and LC/MS/MS analysis.” Supervisor: Prof.ssa Leila Birolo

1998-2003

Maturità Linguistica (100/100) Liceo Scientifico/Scuola Magistrale (Sezione Annessa) "Galilei"

Personal skills and competences Foreign languages

English

Technical skills

Extraction and purifications of bioactive lipids from tissues and cells Quantification of bioactive lipids by LC/MS and LC/MS/MS analysis Cell coltures Biochemical assays (ABPP, MudPIT, SDS-PAGE, Western blot) in cells and tissues Enzymatic assays

IT skills: Microsoft Power Point, Microsoft Word, Microsoft Excel Microsoft Outlook Internet Mascot MS/MS ion search

ChemBioDraw Graphpad Prism ImageJ

Scientific publications H-index= 19 (source Scopus) 1) A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Niphakis MJ, Lum KM, Cognetta AB 3rd, Correia BE, Ichu TA, Olucha J, Brown SJ, Kundu S, Piscitelli F, Rosen H, Cravatt BF. Cell. 2015;161:1668-80 2) Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signalling Deficiency. Cristino L, Luongo L, Imperatore R, Boccella S, Becker T, Morello G, Piscitelli F, Busetto G, Maione S, Di Marzo V. Neuropsychopharmacology. 2015 [Epub ahead of print] 3) Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons. Vähätalo LH, Ruohonen ST, Mäkelä S, Ailanen L, Penttinen AM, Stormi T, Kauko T, Piscitelli F, Silvestri C, Savontaus E, Di Marzo V. Nutr Diabetes. 2015;5:e151. 4) Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons. Palomba L, Silvestri C, Imperatore R, Morello G, Piscitelli F, Martella A, Cristino L, Di Marzo V. J Biol Chem. 2015;290:13669-77. 5) Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, Di Marzo V, de Lago E, Fernández-Ruiz J. J Neuroimmune Pharmacol. 2015;10(2):233-44. 6) Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. Altamura C, Ventriglia M, Martini MG, Montesano D, Errante Y, Piscitelli F, Scrascia F, Quattrocchi C, Palazzo P, Seccia S, Vernieri F, Di Marzo V. J Alzheimers Dis. 2015. [Epub ahead of print] 7) Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Bashashati M, Nasser Y, Keenan CM, Ho W, Piscitelli F, Nalli M, Mackie K, Storr MA, Di Marzo V, Sharkey KA. Br J Pharmacol. 2015;172(12):3099-111. 8) Deranged endocannabinoid responses to hedonic eating in underweight and recently weightrestored patients with anorexia nervosa. Monteleone AM, Di Marzo V, Aveta T, Piscitelli F, Dalle Grave R, Scognamiglio P, El Ghoch M, Calugi S, Monteleone P, Maj M. Am J Clin Nutr. 2015;101:2629. 9) Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Rubino T, Prini P, Piscitelli F, Zamberletti E, Trusel M, Melis M, Sagheddu C, Ligresti A, Tonini R, Di Marzo V, Parolaro D. Neurobiol Dis. 2015;73:60-9. 10) 11) The endocannabinoid system mediates aerobic exercise-induced antinociception in rats.“ Galdino G, Romero TR, Silva JF, Aguiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F, Duarte ID, Di Marzo V, Perez AC. Neuropharmacology. 2013; 77C:313-324. 12) “The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.” Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, Sagredo O, Di Marzo V, Fernández-Ruiz J. Cell Death Dis. 2013;4:e862. 13) “Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons.” Varga A, Jenes A, Marczylo TH, Sousa-Valente J, Chen J, Austin J, Selvarajah S, Piscitelli F, Andreou AP, Taylor AH, Kyle F, Yaqoob M, Brain S, White JP, Csernoch L, Di Marzo V, Buluwela L, Nagy I. Pflugers Arch. 2013 [Epub ahead of print].

14) “Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.” Maione S, Costa B, Piscitelli F, Morera E, De Chiaro M, Comelli F, Boccella S, Guida F, Verde R, Ortar G, Di Marzo V. Pharmacol Res. 2013;76:98105. 15) “Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats.” Iannotti FA, Piscitelli F, Martella A, Mazzarella E, Allarà M, Palmieri V, Parrella C, Capasso R, Di Marzo V. Prostaglandins Leukot Essent Fatty Acids. 2013;89(2-3):127-35. 16) “Anandamide-derived prostamide F2α negatively regulates adipogenesis.” Silvestri C, Martella A, Poloso NJ, Piscitelli F, Capasso R, Izzo A, Woodward DF, Di Marzo V. J Biol Chem. 2013;288(32):23307-21. 17) “Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men.” Berge K, Piscitelli F, Hoem N, Silvestri C, Meyer I, Banni S, Di Marzo V. Lipids Health Dis. 2013;12:78. 18) "Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on astrogliogenesis through the endocannabinoid system.” Shinjyo N, Piscitelli F, Verde R, Di Marzo V. J Neurosci Res. 2013;91(7):943-53. 19) “Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study.” Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli F, Prud' Homme D, Di Marzo V. 2013 Obesity (Silver Spring). [Epub ahead of print]. 20) “Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.” Descalzi F, Ulivi V, Cancedda R, Piscitelli F, Luongo L, Guida F, Gatta L, Maione S, Di Marzo V.Tissue Eng Part A. 2013;19(19-20):2120-9. 21) “The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.” Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A. Br J Pharmacol. 2013;169(1):213-29. 22) “Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat.” Naudon L, Piscitelli F, Giros B, Di Marzo V, Daugé V. Neuropharmacology. 2012; 65:193-9. 23) ““Redundancy” of endocannabinoid inactivation: new challenges and opportunities for pain control.” Piscitelli F, Di Marzo V. ACS Chem. Neurosci., 2012;3:356–363. 24) "Chronic Blockade of CB1 Receptors Reverses Startle Gating Deficits and Associated Neurochemical Alterations in Isolation Reared Rats.” Zamberletti E, Piscitelli F, Cadeddu F, Rubino T, Fratta W, Fadda P, Di Marzo V, Parolaro D. Br J Pharmacol. 2012; 167(8):1652-64. 25) “Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability.” Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, Di Marzo V. PLoS One. 2012;7:e31111. 26) “Hedonic Eating Is Associated with Increased Peripheral Levels of Ghrelin and the Endocannabinoid 2-Arachidonoyl-Glycerol in Healthy Humans: A Pilot Study.” Monteleone P, Piscitelli F, Scognamiglio P, Monteleone AM, Canestrelli B, Di Marzo V, Maj M.J Clin Endocrinol Metab. 2012; 97(6):E917-24. 27) “Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.” Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, Gallo L, Capasso F, Orlando P, Di Marzo V. Br J Pharmacol. 2012;166:1444-60. 28) “Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.” Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, Di Marzo V, Izzo AA. J Mol Med (Berl). 2012; 90(8):925-34. 29) “Spinal anandamide produces analgesia in neuropathic rats: Possible CB(1)- and TRPV1-mediated mechanisms.” Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V, Przewlocka B. Neuropharmacology. 2012;62(4):1746-55. 30) “TRPV1-Dependent and -Independent Alterations in the Limbic Cortex of Neuropathic Mice: Impact on Glial Caspases and Pain Perception.“ Giordano C, Cristino L, Luongo L, Siniscalco D,

Petrosino S, Piscitelli F, Marabese I, Gatta L, Rossi F, Imperatore R, Palazzo E, de Novellis V, Di Marzo V, Maione S.Cereb Cortex. 2012; 22(11):2495-518. 31) “The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques.” Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Bertolotto M, Pelli G, Galan K, Pilet L, Kuzmanovic K, Burger F, Pane B, Spinella G, Braunersreuther V, Gayet-Ageron A, Pende A, Viviani GL, Palombo D, Dallegri F, Roux-Lombard P, Santos RA, Stergiopulos N, Steffens S, Mach F. Eur Heart J. 2012;33(7):846-56. 32) “Intense exercise increases circulating endocannabinoid and BDNF levels in humans-Possible implications for reward and depression.” Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B, Leclair E, Di Marzo V, Meeusen R. Psychoneuroendocrinology. 2012;37(6):844-51. 33) “Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats.” Deblon N, VeyratDurebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, Piscitelli F, Legros JJ, Geenen V, Foti M, Wahli W, Di Marzo V, Rohner-Jeanrenaud F. PLoS One. 2011;6:e25565. “Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.” Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, Salvidio G, Di Marzo V, Cavallo Perin P, Gruden G. Diabetes. 2011;60:2386-96. 34) “Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice.” Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS, Griinari M, Banni S, Di Marzo V. Nutr Metab (Lond). 2011;8:51. 35) “Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.” Di Marzo V, Piscitelli F, Mechoulam R. Handb Exp Pharmacol. 2011;:75-104. 36) “Gut feelings about the endocannabinoid system.” Di Marzo V, Piscitelli F. Neurogastroenterol Motil. 2011;23:391-8. 37) “The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats.” de Novellis V, Vita D, Gatta L, Luongo L, Bellini G, De Chiaro M, Marabese I, Siniscalco D, Boccella S, Piscitelli F, Di Marzo V, Palazzo E, Rossi F, Maione S. Mol Pain. 2011;17;7:7. 38) “N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity.” De Petrocellis L, Guida F, Moriello AS, De Chiaro M, Piscitelli F, de Novellis V, Maione S, Di Marzo V. Pharmacol Res. 2011;63:294-9. 39) “Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetised rats through several mechanisms of action.” Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, De Novellis V, Di Marzo V. Br J Pharmacol. 2011;162(3):584-96. 40) “Endocannabinoid modulation in the olfactory epithelium.” Breunig E, Czesnik D, Piscitelli F, Di Marzo V, Manzini I, Schild D. Results Probl Cell Differ. 2010;52:139-45. Contributo: Stesura. 41) “The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of Xenopus laevis.” Breunig E, Manzini I, Piscitelli F, Gutermann B, Di Marzo V, Schild D, Czesnik D. J Neurosci. 2010;30:8965-73. 42) “Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients.” Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, Bozzetto L, Riccardi G, Verde R, Petrosino S, Rivellese AA, Di Marzo V. Lipids Health Dis. 2010;28:9-43. 43) “Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans.” Bordicchia M, Battistoni I, Mancinelli L, Giannini E, Refi G, Minardi D, Muzzonigro G, Mazzucchelli R, Montironi R, Piscitelli F, Petrosino S, Dessì-Fulgheri P, Rappelli A, Di Marzo V, Sarzani R. Metabolism. 2010;59:734-741. 44) “Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.” Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M, Domenicali M, Petrosino S, Giampalma E, Riili A, Grazi G, Golfieri R, Zoli M, Bernardi M, Di Marzo V. Liver Int. 2010;30:816-825.

45) “Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects.” Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van Gaal L, Taskinen MR.Eur J Endocrinol. 2009; 161:715-22. 46) “Basal and Fasting/Refeeding-regulated Tissue Levels of Endogenous PPAR-alpha Ligands in Zucker Rats.” Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, Di Marzo V.Obesity (Silver Spring). 2010;18:55-62. 47) “Peripheral endocannabinoid dysregulation in two experimental models of obesity: potential relationships with intestinal motility and food deprivation/refeeding-induced energy processing.” Izzo AA, Piscitelli F, Capasso R, Gabriella Aviello, Barbara Romano, Francesca Borrelli, Stefania Petrosino, Vincenzo Di Marzo. Br J Pharmacol. 2008;158:451–461. 48) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP. Diabetologia 2009;52:213-7. 49) “Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics.” Bisogno T, Piscitelli F, Di Marzo V. Eur. J. Lipid Sci. Technol. 2008; 111: 53–63.

Conferences 1) Massa 2015 Alghero, June 10-12, 2015 F.Piscitelli, D. Paris, D. Melck, C. Giordano, L. Luongo, S. Maione, A. Motta, V. Di Marzo. Targeted lipidomics profile and NMR metabolomics of injured mouse brain. Oral presentation 2) The Metabolomics Approaches: Advanced Analytical Tools (Challenges, perspectives and applications) Padova, November 10-11, 2014 F.Piscitelli, D. Paris, D. Melck, C. Giordano, L. Luongo, S. Maione, A. Motta, V. Di Marzo. Targeted lipidomics profile and NMR metabolomics of injured mouse brain; Oral presentation 3) FIRST JOINT SPANISH-ITALIAN MEETING ON CANNABINOID RESEARCH, Madrid (Spain) 29, 30/11 01/12/2012 Piscitelli F., Lichtman A., Sim-Selley L., Hamm R., Bisogno T., Di Marzo V. and Mechoulam R. Targeted lipidomics profiling of injured rat brain: N-oleoyl-glycine and its possible mechanism of action; Oral presentation 4) 22th annual Symposium of the International Cannabinoid Research Society, Freiburg (Germany) 22-27/07/ 2012 Piscitelli F., Lichtman A., Sim-Selley L., Hamm R., Bisogno T., Di Marzo V. and Mechoulam R. Targeted lipidomics profiling of injured rat brain: possible implications for nicotine dependence; Poster. 5) Convegno monotematico SIF “I Cannabinoidi:dalla Biologia alla Clinica”, Cagliari (Italy) 29-30/09/2011

Piscitelli F., Bisogno T., Di Marzo V. Endocannabinoidomics: targeted lipidomics methods for the study of endocannabinoid-relate molecules in the CNS; Oral presentation 6) Cannabinoid Function in the CNS Les Diablerets (Swizterland) 22-27/05/2011 Piscitelli F., Di Marzo V. Endocannabinoidomics: targeted lipidomics methods for the study of endocannabinoid-relate molecules in the CNS; Poster. 7) Cannabinoid Function in the CNS- Gordon-Kenan Research Seminar-“Dysregulation of the Endocannabinoid System and Ensuing Pathological States” Les Diablerets (Swizterland) 21-22/05/2011 Piscitelli F., Di Marzo V. Endocannabinoidomics: targeted lipidomics methods for the study of endocannabinoid-relate molecules in the CNS; Oral presentation 8) Cannabinoids in Biology and Medicine, Jerusalem (Israel) 31/10-4/11/2010 Piscitelli F., Sirigu AR., Bisogno T., Vacca C., Berge K., Tandy S., Cohn JS., Banni S., Di Marzo V. Lipid profiling of high-fat-fed mice after dietary krill oil supplementation; Poster. 9) Riunione Nazionale Dottorandi e Borsisti italiani in Neuroscienze e Materie Affini, Busto Arsizio (Italy) 27-28/05/2010 Piscitelli F., Breunig E., Manzini I., Gutermann B., Di Marzo V., Schild D., Czesnik D. The endocannabinoid 2-AG controls odorant detection threshold in larvae of Xenopus Laevis; Poster. 10) 19th annual Symposium of the International Cannabinoid Research Society, Pheasant Run, St. Charles, Illinois (USA) 7-11/07/2009 Piscitelli F., Izzo A.A., Capasso R., Petrosino S., Di Marzo V. Alterations of basal and fasting/refeeding-regulated tissue levels of endogenous n-acyl-ethanolamine ligands of PPAR-α in obese Zucker rats; Poster.

Awards 1) Best oral presentation SEIC-IRES meeting (Madrid, 29, 30/11 01/12/2012)

Certifications English: Marzo 2009 Preliminary English Test (PET) Grade: Pass Score: 81/100

Aprile 2003 Trinity Grade:7 Score: Distinction Aprile 2002 Trinity Grade:6 Score: Distinction French: 05/07/04

B1 Expression spécialisée Note finale: 14,00

02/07/03

A6 Expression spécialisée Note finale: 14,00

02/07/03

A5 Civilisation française et francophone Note finale: 14,00

24/02/03

A4 Pratique du fonctionnement de la langue Note finale: 10,00

24/02/03

A3 Compréhension et expression écrites Note finale: 14,67

11/07/02

DELF scolaire niveau 1 (A1-A2) Note finale: 14,75